anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: veterinary. SUBSTANCE: vaccine contains aqueous suspension of Leptospirosis interrorgans strain which is inactivated with formalin and sorbed on aluminium hydroxide in two variants and stabilizing agent. Summary concentration of microbial cells is 0.5-5.0 billions in 1 cm 3  for each of the variant. Mentioned above stabilizing agent contains protein of blood serum, albumin, hemoglobin and phosphate buffer solution having pH 7.2-7.6. Dosage of proposed vaccine for cattle is 250-300 millions of microbial cells (MMC), 500-600 and 600-700 MMC for animals aged 2-6 month, 6-12 month and 1-2 year respectively. Dosage for mature animal having body mass up to 400 kg is 750-800 MMC, that for animals having body mass more 400 kg is 1000-1200 MMC. Dosage for young pigs aged 1-3 and 3-10 month is 350-450 and 450-550 MMC respectively. Dosage for sheep and goats aged 2-6 and 6-12 month is 150-250 and 250-300 MMC respectively. All mentioned above doses are used at volume 0.3-1.0 cm 3 . EFFECT: improves antigenic and immunogenic activity of vaccine.
The invention discloses a composition for treating oral mucositis. The composition is prepared from ropivacaine mesylate and an aluminum hydroxide and magnesium hydroxide suspension in a dose ratio of 0.5-5mg to 1ml. The invention further discloses a method for preparing the composition for treating oral mucositis. The method comprises the following steps: 1, preparing the suspension from hydroxyethyl cellulose, hydroxy propyl cellulose, simethicone, aluminum hydroxide and magnesium hydroxide; 2, adding sorbitol, mannitol and butyl p-hydroxybenzoate to regulate the pH value to obtain the aluminum hydroxide and magnesium hydroxide suspension; and 3, adding ropivacaine mesylate into the aluminum hydroxide and magnesium hydroxide suspension, and uniformly stirring to obtain the suspension for treating oral mucositis. The invention further discloses an application package for the composition for treating oral mucositis. The composition for treating oral mucositis has the advantages of relieving pain and diminishing inflammation, repairing the mucosa ulcer face and the like, and is convenient to use.
Participants randomized to the experimental group attend two group-based class sessions per week, each 1.25hours long, that are led by certified instructors who guide participants through various exercises. Participants are encouraged to practice the activities at home for 20 minutes each day.
Myocardial infarction (MI) is a serious complication of coronary artery disease. This condition is common worldwide and has a profound impact on patients' lives and quality of life. Despite significant advances in the treatment of heart disease in modern medicine, the efficient treatment of MI still faces a number of challenges. Problems such as scar formation and loss of myocardial function after a heart attack still limit patients' recovery. Therefore, the search for a new therapeutic tool that can promote repair and regeneration of myocardial tissue has become crucial. In this context, mesenchymal stromal cells (MSCs) have attracted much attention as a potential therapeutic tool. MSCs are a class of adult stem cells with multidirectional differentiation potential, derived from bone marrow, fat, placenta and other tissues, and possessing properties such as self-renewal and immunomodulation. The application of MSCs may provide a new direction for the treatment of MI. These stem cells have the potential to differentiate into cardiomyocytes and vascular endothelial cells in damaged tissue and to repair and protect myocardial tissue through anti-inflammatory, anti-fibrotic and pro-neovascularization mechanisms. However, the clinical results of MSCs transplantation for the treatment of MI are less satisfactory due to the limitations of the native function of MSCs. Genetic modification has overcome problems such as the low survival rate of transplanted MSCs in vivo and enhanced their functions of promoting neovascularization and differentiation into cardiomyocytes, paving the way for them to become an effective tool for repair therapy after MI. In previous studies, MSCs have shown some therapeutic potential in experimental animals and preliminary clinical trials. This review aims to provide readers with a comprehensive and in-depth understanding to promote the wider application of engineering MSCs in the field of MI therapy, offering new hope for recovery and improved survival of cardiac patients.
Tozorakimab is a human monoclonal antibody that neutralizes interleukin (IL)-33. IL-33 is a broad-acting epithelial "alarmin" cytokine upregulated in lung tissue of patients with chronic obstructive pulmonary disease (COPD). This first-in-human, phase I, randomized, double-blind, placebo-controlled study (NCT03096795) evaluated the safety, tolerability, pharmacokinetics (PKs), immunogenicity, target engagement, and pharmacodynamics (PDs) of tozorakimab. This was a 3-part study. In part 1, 56 healthy participants with a history of mild atopy received single escalating doses of either intravenous or subcutaneous tozorakimab or placebo. In part 2, 24 patients with mild COPD received multiple ascending doses of subcutaneous tozorakimab or placebo. In part 3, 8 healthy Japanese participants received a single intravenous dose of tozorakimab or placebo. The safety data collected included treatment-emergent adverse events (TEAEs), vital signs, and clinical laboratory parameters. Biological samples for PKs, immunogenicity, target engagement, and PD biomarker analyses were collected. No meaningful differences in the frequencies of TEAEs were observed between the tozorakimab and placebo arms. Three tozorakimab-treated participants with COPD experienced treatment-emergent serious adverse events. Subcutaneous or intravenous tozorakimab demonstrated linear, time-independent PKs with a mean half-life of 11.7-17.3 days. Treatment-emergent anti-drug antibody frequency was low. Engagement of tozorakimab with endogenous IL-33 in serum and nasal airways was demonstrated. Tozorakimab significantly reduced serum IL-5 and IL-13 levels in patients with COPD compared with placebo. Overall, tozorakimab was well tolerated, with a linear, time-independent serum PK profile. Additionally, biomarker studies demonstrated proof of mechanism. Overall, these data support the further clinical development of tozorakimab in COPD and other inflammatory diseases.
Adults and Pediatric Patients 10 Years of Age and Older

The recommended dose for topiramate monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doses. The dose should be achieved by titration according to the following schedule (Table 1): 

Pediatric Patients 2 to 9 Years of Age

Dosing in patients 2 to 9 years of age is based on weight. During the titration period, the initial dose of topiramate is 25 mg/day nightly for the first week. Based upon tolerability, the dosage can be increased to 50 mg/day (25 mg twice daily) in the second week. Dosage can be increased by 25 to 50 mg/day each subsequent week as tolerated. Titration to the minimum maintenance dose should be attempted over 5 to 7 weeks of the total titration period. Based upon tolerability and clinical response, additional titration to a higher dose (up to the maximum maintenance dose) can be attempted at 25 to 50 mg/day weekly increments. The total daily dose should not exceed the maximum maintenance dose for each range of body weight (Table 2).
Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
Nocturia has been increasingly recognized as a manifestation of various non-urological conditions including hypertension. In adults, blood pressure (BP) elevation has been identified as a robust correlate of nocturia, but such a relationship has not been studied in pediatric populations where nocturia is often attributed to hormonal, sleep, physiological or psychological disorders. Accordingly, this study aimed to determine the relationship between nocturia and BP elevation in adolescents. We prospectively studied 100 patients, aged 10-18 years, recruited from pediatric clinics at our institution. Nocturia (defined as ≥ 1 voids on voiding diary analysis) was present in 45% of the study sample (range: 1-4 voids/night). 37% of subjects self-reported awakening to urinate, and 34% of subjects had BP elevation according to age-dependent thresholds from current Pediatrics guidelines. On multivariate analyses, BP elevation was strongly associated with nocturia determined by both voiding diary (OR 26.2, 95% CI: 6.5, 106.0) and self-report. Conversely, nocturia was associated with increased odds of elevated BP by diary (26.3, 95% CI: 6.5, 106.4) and self-report (OR 8.1, 95% CI: 3.2, 20.5). In conclusion, nocturia appears to be common and is strongly associated with BP elevation in adolescents. These findings suggest that eliciting a history of nocturia holds promise as a simple method of identifying adolescents at risk for hypertension.
OBJECTIVES: To develop and validate a risk model for 1-year mortality based on variables available from early prehospital emergency attendance of patients with infection.
MATERIAL AND METHODS: Prospective, observational, noninterventional multicenter study in adults with suspected infection transferred to 4 Spanish hospitals by advanced life-support ambulances from June 1, 2020, through June 30, 2022. We collected demographic, physiological, clinical, and analytical data. Cox regression analysis was used to develop and validate a risk model for 1-year mortality.
RESULTS: Four hundred ten patients were enrolled (development cohort, 287; validation cohort, 123). Cumulative mortality was 49% overall. Sepsis (infection plus a Sepsis-related Organ Failure Assessment score of 2 or higher) was diagnosed in 29.2% of survivors vs 56.7% of nonsurvivors. The risk model achieved an area under the receiver operating characteristic curve of 0.89 for 1-year mortality. The following predictors were included in the model: age; institutionalization; age-adjusted Charlson comorbidity index; PaCO2; potassium, lactate, urea nitrogen, and creatinine levels; fraction of inspired oxygen; and diagnosed sepsis.
CONCLUSION: The model showed excellent ability to predict 1-year mortality based on epidemiological, analytical, and clinical variables, identifying patients at high risk of death soon after their first contact with the health care system.
Cervical cancer is primarily caused by Human Papillomavirus (HPV) infection and remains a significant public health concern, particularly in Latin American regions. This comprehensive narrative review addresses the relationship between Human Papillomavirus (HPV) and cervical cancer, focusing on Latin American women. It explores molecular and immunological aspects of HPV infection, its role in cervical cancer development, and the epidemiology in this region, highlighting the prevalence and diversity of HPV genotypes. The impact of vaccination initiatives on cervical cancer rates in Latin America is critically evaluated. The advent of HPV vaccines has presented a significant tool in combating the burden of this malignancy, with notable successes observed in various countries, the latter due to their impact on immune responses. The review synthesizes current knowledge, emphasizes the importance of continued research and strategies for cervical cancer prevention, and underscores the need for ongoing efforts in this field.
PURPOSE: A photoresponsive vesicle containing a water soluble target material is provided to control release of the target material from the vesicle. CONSTITUTION: A photoresponsive vesicle contains a water soluble target material. The vesicle contains coumarin on the membrane and can control release of the water soluble target materials. The coumarin includes coumarin, 7-hydroxy coumarin, carboxyl coumarin, or acetoxy coumarin. An amphipathic molecule forming the vesicle is phosphatidylcholine or phosphatidylethanolamine. A method for preparing the vesicle comprises: a step of dissolving coumarin and amphipathic molecules in an organic solvent and forming a dry membrane of coumarin/amphipathic molecules; a step of adding a water soluble target material dissolved in an aqueous phase to the membrane and homogenizing; and a step of removing unloaded courmarin and target materials.
OBJECTIVE: Olfactory tests tailored for children are essential, as diagnosing olfactory dysfunction at these ages can be challenging. The 16-item "Sniffin' Sticks" is reliable and easy to perform. To the best of our knowledge, there is currently no validated olfactory test for the Portuguese pediatric population. This study aimed to adapt and validate the "Sniffin' Sticks" olfactory test for the Portuguese pediatric population.
METHODS: Between August 2020 and September 2021, 354 children aged between 6 and 17years old enrolled in the study, 336 healthy children with a normal sense of smell, and 18 anosmic children with Kallmann syndrome. The study consisted of two parts. Firstly, the "Sniffin' Sticks" olfactory identification test was applied to healthy children and the odors with statistically significant low identification rates were excluded. A modified version of "Sniffin' Sticks" was defined and named "Sniffin' Kids-PT" test. Secondly, normative data were assessed and test-retest and validation tests were performed.
RESULTS: Apple and Cloves odors were identified with a low rate and were excluded from the "Sniffin' Sticks" olfactory test. In the modified 14-item "Sniffin' Kids-PT", scoring <6 (from 6-8years old), <7 (from 9-11years old) or <8 (from 12-14years old and 15-17years old) was indicative of olfactory dysfunction. The test-retest reliability was good (r=0.81; P<0.001) and the differences between scores of healthy children and anosmic children were statistically significant (U213=13.00; P<0.001).
CONCLUSION: The modified "Sniffin' Kids-PT" is a reliable test to discriminate between normosmia and olfactory dysfunction in Portuguese children over 5years old.
Twelve weeks of 1100 mg of maltodextrin. This product is an enzymatically converted potato starch. The flavor and color will have a similar/identical appearance and taste as all mentioned antioxidants.
Identifying agents (A) for detection or treatment of specified conditions comprises incubating test compound with BNPI or DNPI (brain or differentiation-associated sodium-dependent inorganic phosphate transporter), or related proteins, nucleic acids or cells (and/or cell preparations), then measuring binding of test compound or some functional parameter altered by binding. Identifying agents (A) for detection or treatment of specified conditions comprises incubating test compound with BNPI or DNPI (brain or differentiation-associated sodium-dependent inorganic phosphate transporter), or related proteins, nucleic acids or cells (and/or cell preparations), then measuring binding of test compound or some functional parameter altered by binding. (A) is incubated with one or more of BNPI or DNPI, or 7 specified proteins, all fully disclosed in the specification; proteins with at least 90% similarity; proteins encoded by 7 specified nucleic acid sequences all fully disclosed in the specification, by sequences with at least 90% similarity, by sequences that hybridize to them (or their antisense sequences) under stringent conditions, or fragments of the proteins with at least 10, preferably 20, amino acids. An independent claim is also included for compounds identified by the new method. ACTIVITY : Ophthalmological; Auditory; Neuroleptic: Antimanic; Antidepressant; Cerebroprotective; Neuroprotective; Analgesic; Anorectic; Anticonvulsant; Antiparkinsonian; Vasotropic; Antiemetic; Antiarthritic; Tranquilizer; Virucide; Antibacterial; Protozoacide; Antiinflammatory; Cardiant; Hypotensive; Antiasthmatic; Immunosuppressive; Antidiabetic; Antialcoholic; Anti-HIV; Nootropic; Antiallergic. No details of tests for any of these activities are given. MECHANISM OF ACTION : None given.
Aim: This research examined the correlation between miR-559 rs58450758 and the clinical pathological characteristics and prognosis of CRC.Materials & methods: RT-qPCR was utilized to assess the miR-559 expression levels. Chi-square test was used to investigate the relationship between miR-559 and clinical features. The association between rs58450758 different genotypes and CRC risk, as well as clinical pathological parameters, was explored, utilizing logistic regression analysis and chi-square tests. The Cox regression model and Kaplan-Meier analysis evaluated overall survival in individuals with CRC.Results: The miR-559 was down-regulated in CRC patients' serum. The expressions of miR-559 were significantly associated with tumor size, differentiation, TNM stage and lymph node metastasis. The rs58450758 TT genotype and T allele carriers were more prevalent among CRC patients. The rs58450758 polymorphism was notably linked to tumor size, differentiation, TNM stage and lymph node metastasis in CRC patients. Furthermore, CC genotype carriers exhibited a longer survival period than CT/TT genotypes within the CRC population.Conclusion: The miR-559 rs58450758 polymorphism exhibits promise as a potential biomarker for prognosticating the outcomes of CRC.
FIELD: medical engineering. SUBSTANCE: system for performing transcutaneous drug administration has at least two active elements and composed of at least two combined means. The first means is composed of all active elements mixture. The first means contains at least one first element A in the amount required for making one effective therapeutic dose to be introduced, and one second element B which amount is less than it is required for supplying one effective therapeutic dose, and one or several additional means each of which has one active element B selected from those contained in the first means in the amount less than it is required for administering one effective therapeutic dose. The mentioned one or several additional means supply every active element B contained in the system in the amount required for obtaining one effective therapeutic dose. EFFECT: reduced means surface area; enabled adaptation of several suitable doses of acceptable size. 8 cl
PROBLEM TO BE SOLVED: To produce an W/O/W emulsion having a good stability with high yield by dispersing an W/O emulsion in a gel-liquid crystal compsn. at a temp. near the phase transition temp. of the gel-liquid crystal compsn. from the gel phase to the liquid phase, and then cooling the dispersion. SOLUTION: When an W/O/W emulsion having good stability is produced with high yield, such a gel-liquid crystal compsn. is used as a dispersion medium to disperse the W/O emulsion that shows a gel phase at normal temp. and causes phase transition to a liquid crystal phase at a specified temp. (phase transition temp.) higher than the normal temp. and that is in a liquid phase in the temp. range over the phase transition temp. Then a W/O emulsion is dispersed in the dispersion medium of the gel-liquid crystal compsn. above described at a temp; near the phase transition temp. of the gel-liquid crystal compsn., and then cooled to obtain a W/O/W emulsion. The compounding ratio of the water phase component which constitutes the inner phase of the W/O emulsion to the oil phase component which constitutes the outer phase is preferably 2:1 to 1:2 by weight.
Organic digital education (ODE) includes online medical education content that can take various forms, such as blogs, social media, videos, podcasts, or infographics. Multimedia ODE platforms have unique benefits and have quickly become an essential part of medical education. Modern medical educators with competency in digital teaching modalities can leverage these for teaching as well as career development and dissemination of scientific research. The ID Digital Institute is a digital education program with a curriculum designed to equip infectious diseases (ID) professionals with the skills to appraise, create, curate, and integrate ODE into their teaching and career. We share the structure, content, and lessons learned from the ID Digital Institute program. We also illustrate how digital education skills can present unique opportunities to align with current and future transplant and immunocompromised host infectious diseases education efforts.
Intervention included provision of power wheelchair and power mobility training program. Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
BACKGROUND: Rebleeding after endoscopic treatment for esophagogastric varices (EGVs) in cirrhotic patients remains a significant clinical challenge, with high mortality rates and limited predictive tools. Current methods, relying on clinical indicators, often lack precision and fail to provide personalized risk assessments. This study aims to develop and validate a novel, non-invasive prediction model based on CT radiomics to predict rebleeding risk within one year of treatment, integrating radiomic features from key organs and clinical data.
METHODS: 123 patients were enrolled and divided into rebleeding (n = 44) and non-bleeding group (n = 79) within 1 year after endoscopic treatment of EGVs. The liver, spleen, and the lower part of the esophagus were segmented and the extracted radiomics features were selected to construct liver/spleen/esophagus radiomics signatures based on logistic regression. Clinic-radiomics combined models and multi-organ combined radiomics models were constructed based on independent model scores using logistic regression. The model performance was evaluated by ROC analysis, calibration and decision curves. The continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indices were analyzed.
RESULTS: The clinical-liver combined model had the highest AUC of 0.931 (95% CI: 0.887-0.974), which was followed by the liver-based model with AUC of 0.891 (95% CI: 0.835-0.74). The decision curves also showed that the clinical-liver combined model afforded a greater net benefit compared to other models within the threshold probability of 0.45 to 0.80. Significant improvements in discrimination (IDI, P < 0.05) and reclassification (NRI, P < 0.05) were obtained for clinical-liver combined model compared with the independent ones.
CONCLUSION: The independent and combined liver-based CT radiomics models performed well in predicting rebleeding within 1 year after endoscopic treatment of EGVs.